Event Preview | The ‘2026 Global Synthetic Biology Industry Development Blue Book’ will be released at the Frost & Sullivan Life Science New Investment Summit Health Technology Session

Definition of synthetic biology and strategic significance of the industry

Synthetic biology vs. bio manufacturing: conceptual definition, logical relationship, and boundaries (avoiding the broad interpretation of 'everything can be synthetic biology'); narrative coordinates of the three revolutions in life science: reading DNA → modifying DNA → writing/reprogramming life systems; macro driving force model: Dual Carbon constraints × Supply chain security × New quality productivity × upgrading health needs; synthetic biology has become a strategically important industry and sector worldwide.

Evolution of key technologies in synthetic biology and analysis of leading and innovative technologies

Innovative technologies are particularly prominent in the development of synthetic biology. CRISPR technology at the gene level reshapes underlying code; AI x synthetic biology creates protein language models; cell-free synthesis and modular construction build core factories; DBTL automation and standardization (DoE + high throughput + online sensing + digital twin) enable 'replicable manufacturing' of biotechnology. This deep analysis of innovative and leading technologies in the field, combined with descriptions of industry-leading and product-innovation technologies and products in related fields, is presented.

Full industrial chain map and value chain breakdown of synthetic biology

Analyzing upstream (tool layer), midstream (platform layer), and downstream (application layer) of synthetic biology, and examining its applications in: ① biomedicine (production intermediates, bacterial engineering, artificial viruses, controlled cell and gene therapy); ② food and nutrition (alternative proteins, nutritional additives, flavors); ③ agriculture (breeding, fertilizers); ④ high-performance materials (new polymer materials, high-performance proteins, living functional materials); ⑤ consumer personal care (multifunctional proteins, functional small molecules); ⑥ bulk chemicals; ⑦ bioenergy, with detailed analysis of enterprises in the upstream and downstream of the industrial chain.

Country/Region Comparisons of Synthetic Biology: Analysis of industrial ecosystem and regulatory frameworks

Currently, synthetic biology is a key research area in major countries around the world. This report analyzes the industrial ecosystems and regulatory frameworks in China, the United States, the European Union (UK), Middle East and BRI core countries.

Analysis of financing, core challenges, and future development trends in synthetic biology

Analyzing the comparison of profit models among three types of enterprises in synthetic biology: IP licensing (platform-based), proprietary products (vertical), and CDMO outsourcing (asset-intensive). Reviewing the financing cycle, including the decline of the 'capacity narrative' and the resurgence of 'cash flow + product selection barriers'. Whether it is possible to upgrade bio manufacturing, achieve standards/safety/testing compliance, and ensure performance/purity/consistency and traceability, and achieve stable quality control globally, clear regulations, and auditable processes will become growth points for the industry. This also analyzes the future development trends and challenges faced by the synthetic biology industry.

Introduction to Synthetic Biology Enterprises

The blue book will include partner enterprises, presenting the business areas, product layouts, technology platforms, and differentiated advantages of upstream and downstream enterprises in the synthetic biology industry, highlighting the product characteristics and competitive advantages of partner enterprises.